Abstract:In the current study we suggest a novel approach to curb non-alcoholic steatohepatitis (NASH) progression, and we suggest privileged scaffolds for the design of novel compounds for this aim. NASH is an advanced form of non-alcoholic fatty liver disease that can further progress into fibrosis, cirrhosis, and hepatocellular carcinoma. It is a widely emerging disease affecting 25% of the global population and has no current approved treatments. Protein kinases are key regulators of cellular pathways, of which, Rho-associated protein kinase 1 (ROCK1) and apoptosis signal–regulating kinase 1 (ASK1) play an important role in the progression of NASH and they stand out as promising targets for NASH therapy. Interestingly, their kinase domains are found to be similar in sequence and topology; therefore, dual inhibition of ROCK1 and ASK1 is expected to be amenable and could achieve a more favourable outcome. To reach this goal, a training set of ROCK1 and ASK1 protein structures co-crystalized with type 1 (ATP-competitive) inhibitors was constructed to manually generate receptor-based pharmacophore models representing ROCK1 and ASK1 inhibitors' common pharmacophoric features. The models produced were assessed using a test set of both ROCK1 and ASK1 actives and decoys, and their performance was evaluated using different assessment metrics. The best pharmacophore model obtained, showing a Mathew's correlation coefficient (MCC) of 0.71, was then used to screen the ZINC purchasable database retrieving 6178 hits that were filtered accordingly using several medicinal chemistry and pharmacokinetics filters returning 407 promising compounds. To confirm that these compounds are capable of binding to the target kinases, they were subjected to molecular docking simulations at both protein structures. The results were then assessed individually and filtered, setting the spotlight on various privileged scaffolds that could be exploited as the nucleus for designing novel ROCK1/ASK1 dual inhibitors.

Identification of protein partners for small molecules reshapes the understanding of nonalcoholic steatohepatitis and drug discovery

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Proteomic Analysis of Liver Mitochondria from Rats with Nonalcoholic Steatohepatitis

Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis

Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

Oligonucleotide Therapies for Nonalcoholic Steatohepatitis

Lipidation-dimerization Platform Unlocks Treatment Potential of Fibroblast Growth Factor 21 for Non-Alcoholic Steatohepatitis

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis

Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal–regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Discovery of an Insulin-Induced Gene Binding Compound That Ameliorates Nonalcoholic Steatohepatitis by Inhibiting Sterol Regulatory Element-Binding Protein-Mediated Lipogenesis.

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

NAFLD and NASH: etiology, targets and emerging therapies

Current and future pharmacological therapies for NAFLD/NASH